Currently, tyrosine kinase inhibitors (TKIs), including erlotinib, gefitinib, dacomitinib, afatinib, and osimertinib, are the standard first-line treatment for advanced NSCLC patients with EGFR mutations [5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.